Official close
$48.17
−$1.69 · −3.39%
Boston Scientific Drops 3.4%, $2.5 Billion Value Lost Following Global Cyberattack
MARLBOROUGH, Massachusetts, August 27, 2026, 04:10 – Shares in Boston Scientific slid 3.4%, wiping out $2.5 billion in market value, after the company was affected by a worldwide cyberattack.
Boston Scientific · NYSE:BSX
Cyberattack investor dashboard
Order processing and customer shipments disrupted worldwide
Market data: August 26, 2026 close, EDT
Premarket: August 27, 2026, 04:01 EDT
Premarket: August 27, 2026, 04:01 EDT
Premarket
$48.40
+$0.23 · +0.48%
04:01 EDT, Aug. 27
Volume
36.56M
1.73× three-month average
Value erased
≈$2.49B
$1.69 × 1.4748B diluted shares
The market repriced restoration risk
The close recovered 2.71% from the intraday low but remained 3.39% below the prior close.
Q3 sales exposure: scenario, not forecast
Guided midpoint $5.268B
× Evercore growth-impact scenario 6%–7%
= $316M–$369M
× Evercore growth-impact scenario 6%–7%
= $316M–$369M
Evercore’s estimate is a 600–700 basis-point hit to third-quarter revenue growth. Boston Scientific has not quantified an impact.
Why the $2.49B selloff is notable
6.8×–7.9×
The estimated equity-value loss divided by the $316M–$369M sales scenario.
The gap prices more than deferred sales. It also reflects uncertainty around margins, remediation, customers, regulation and data exposure.
Operating baseline before the attack
| Metric | Latest figure | Growth / margin | Investor signal |
|---|---|---|---|
| Q2 2026 net sales | $5.442B | +7.5% reported | Growth exceeded Q3’s 3%–5% guide |
| Cardiovascular sales | $3.624B | +8.3% | 66.6% of Q2 revenue |
| MedSurg sales | $1.818B | +5.9% | 33.4% of Q2 revenue |
| Gross profit | $3.848B | 70.7% margin | Expedited freight or remediation could pressure margin |
| Adjusted EPS | $0.86 | FY guide $3.28–$3.32 | Guidance risk depends on restoration time |
Valuation and expectations
| Market capitalization | $69.81B |
| Trailing P/E | 20.2× |
| Forward P/E | 15.2× |
| Enterprise value / revenue | 4.02× |
| Average analyst target | $62.69 |
| Implied upside to close | 30.1% |
Valuation metrics were reported as of August 25; market capitalization uses the August 26 close. Consensus target: 31 analysts.
Peer-session context
August 26 official closes. The wider BSX decline points to company-specific incident risk.
Risks still unpriced precisely
Restoration Deferred sales Data exposure RegulationThe company has not identified the attacker, disclosed whether protected information was accessed, or estimated the financial impact. Longer disruption could add freight, remediation and support costs.
Comparable event
≈1 month
Stryker’s March 2026 attack disrupted order processing, manufacturing and shipping. Most manufacturing returned in about two weeks; full restoration followed roughly one month after detection. Stryker later expected no material 2026 guidance impact.
Wendy’s Shares Drop 13.3% After Hours Following Trian Statement Ruling Out Bid
Shares in The Wendy’s Company dropped after Reuters disclosed that Trian Fund Management, led by Nelson Peltz, does not presently intend to make an offer for the fast-food chain. The stock declined $1.20 in after-hours trading to reach $7.84 at 19:59 EDT.
NASDAQ: WEN · takeover premium reset
Wendy’s investor dashboard
Market data: Aug. 26, 2026, 19:59 EDT
Dashboard prepared: Aug. 27, 2026, 05:08 CEST
Dashboard prepared: Aug. 27, 2026, 05:08 CEST
After-hours price
$7.84
−13.27% · −$1.20
Quoted value erased
≈$229M
$1.20 × 190.67M shares
Analyst target gap
+$0.05
0.6% above $7.79 average
After-hours volume
2.52M
31.6% of regular-session volume
Bid-premium path
Regular closesAfter-hours repricing
Market-value bridge
Aug. 11 close$7.55≈$1.44B
Aug. 26 close$9.04≈$1.72B
Aug. 26 AH$7.84≈$1.49B
- The late drop exceeded the roughly $212M added on Aug. 12.
- Only about $55M of price uplift remained versus Aug. 11.
- Trian owns about 16%; no formal bid price exists.
Operating dashboard · Q2 2026
| Metric | Result | Year over year |
|---|---|---|
| Revenue | $570.6M | +1.7% |
| U.S. same-restaurant sales | — | −7.0% |
| U.S. systemwide sales | $2.88B | −8.2% |
| U.S. restaurant margin | 13.8% | −240 bps |
| Operating profit | $79.3M | −24.0% |
| Net income | $32.6M | −40.8% |
| H1 free cash flow | $120.3M | +9.9% |
Estimate pressure
FactSet current estimates on Aug. 26. One month earlier: $0.14, $0.57 and $0.64, respectively.
Peer valuation
| Company | P/E | Consensus |
|---|---|---|
| Wendy’s | 13.7x | Hold |
| Restaurant Brands | 21.4x | Buy |
| Yum! Brands | 19.5x | Buy |
What moves the stock next
Deal path
A changed Trian stance, another bidder or a formal filing would rebuild optionality.
Traffic
U.S. same-store sales must improve from the Q2 decline.
Margins
Commodity and wage inflation are pressuring restaurant economics.
Next report
Q3 earnings are expected Nov. 11, 2026.
Sources: Reuters, The Wendy’s Company Q2 2026 release, FactSet via The Wall Street Journal, StockAnalysis and Investing.com. Market-value calculations use 190.67 million shares outstanding. After-hours prices can reflect limited liquidity and may not predict the next regular-session open.
Emily in Paris to End With Season 6 on Dec. 24; Netflix Shares Drop 0.9%
Netflix announced on Wednesday that Emily in Paris Season 6 will debut on December 24. The concluding season continues a franchise that secured 30 million views over the past 14 days of 2025.
NASDAQ: NFLX · product/commercial catalyst
A 30M-view franchise gets its final date
Emily in Paris Season 6 lands December 24. The investor test is whether the finale sustains engagement while Netflix expands advertising and absorbs faster content amortization.
Regular close: Aug. 26, 2026, 16:00 EDT
After-hours quote: Aug. 26, 19:24 EDT
Dashboard: Aug. 26, 20:59 EDT
After-hours quote: Aug. 26, 19:24 EDT
Dashboard: Aug. 26, 20:59 EDT
Regular close · Aug. 26
$81.46
−$0.77 · −0.94%
After hours · 19:24 EDT
$80.90
−0.69% from close
Regular volume
22.85M
54% of 65-day average
Market value · close
$342.4B
Day loss ≈$3.2B
Season 6 release file
PremiereDec. 24, 2026
StatusFinal season
Confirmed settingsParis, Greece, Monaco
Episode release patternNot disclosed
Title-level budgetNot disclosed
H2 2025 title engagement · Netflix-defined views
Emily in Paris Season 5 launched December 18, leaving 14 calendar days in the reporting half. Views equal hours watched divided by runtime.
Q2 2026 financial base
Revenue$12.6B
Revenue growth+13%
Operating income$4.2B
Operating margin33.4%
Margin change−70 bps YoY
2026 company outlook
Revenue$51.0B–$51.4B
Revenue growth13%–14%
Operating margin31.5%
Ads revenue≈$3.0B
Content amortization≈+10%
Stock and valuation
52-week range$65.08–$126.71
Below 52-week high−35.7%
P/E ratio25.7×
Shares outstanding4.16B
Short float · Aug. 142.19%
Analyst map · Aug. 26 close
ConsensusModerate Buy
Ratings55
Buy / Hold / Sell37 / 17 / 1
Average target$103.19
The close is 78.9% of the average target; implied upside is 26.7%.
Target range$70–$151.40
Investor bridge
Season 5 produced 30 million views in 14 calendar days. Season 6 can support membership retention and ad inventory, but Netflix reports neither title revenue nor cost. The company-level financial test is 13%–14% revenue growth with a 31.5% margin.
engagementretentionad inventorycontent costWhat can break the thesis
Views are not incremental subscriptions. Existing members may watch without changing churn, pricing power or ad demand. A weak finale could shorten engagement while roughly 10% content-amortization growth weighs on margin.
Dated checkpoints
| Checkpoint | Date |
|---|---|
| Season 6 premiere | Dec. 24, 2026 |
| First-week Top 10 data | After launch |
| Q4 revenue and margin | Next results cycle |
| 2026 ads revenue outcome | Year-end |
Sources: Netflix’s Aug. 26 Season 6 announcement; Netflix H2 2025 Engagement Report; Netflix Q2 2026 shareholder letter filed with the SEC; MarketWatch delayed quote; MarketBeat analyst record. Calculations use the Aug. 26 regular close.
SpaceX Shares Gain 1.2% After $100 Billion Louisiana Starbase Valued at Par With Company Cash
Shares in SpaceX advanced on Wednesday following the announcement of a $100 billion Louisiana spaceport. Space Exploration Technologies Corp. finished the session at $139.63, up 1.22%.
NASDAQ: SPCX · product/commercial catalyst
$100B Starbase meets a $100B cash pool
The Louisiana plan can expand Starship capacity across launch, Starlink and orbital AI. The valuation question is how SpaceX phases a project equal to all second-quarter liquidity.
Regular close: Aug. 26, 2026, 16:00 EDT
After-hours quote: Aug. 26, 16:36 EDT
Dashboard: Aug. 26, 19:58 EDT
After-hours quote: Aug. 26, 16:36 EDT
Dashboard: Aug. 26, 19:58 EDT
Regular close · Aug. 26
$139.63
+$1.68 · +1.22%
After hours · 16:36 EDT
$139.05
−0.42% from close
Regular volume · Aug. 26
56.1M
Yahoo Most Active
Closing market value
≈$1.84T
Project equals 5.4%
Capital scale
Project spending is a total plan, not a disclosed one-year budget. Liquidity and backlog are as of June 30, 2026.
Louisiana buildout
Investment$100B
Site125,000 acres
Launch complexes5
Planned pads10
Construction target2027
First-launch target2029
Q2 2026 financial base
Total revenue$7.81B
Year-over-year growth+92%
Adjusted EBITDA$3.54B
Net result−$541M
Total capex$18.37B
Cash + securities$100B
Space segment
Q2 revenue$962M
Revenue growth+29%
Operating result−$542M
Adjusted EBITDA−$205M
Q2 capex$1.17B
H1 launches78
Commercial channels
Connectivity revenue$4.29B
Starlink subscribers12.0M
AI revenue$2.56B
Government awards>$6B
Total backlog$47.5B
Next resultsNov. 5, 2026
Analyst expectations · Aug. 26 close
ConsensusModerate Buy
Tracked ratings41
Buy / Hold / Sell27 / 8 / 6
Average target$220.20
Close is 63.4% of the average target; implied upside is 57.7%.
Target range$75–$800
Stock map · Aug. 26 close
| Reference | Price | Distance |
|---|---|---|
| 52-week high · June 16 | $225.64 | −38.1% |
| Average analyst target | $220.20 | +57.7% |
| Aug. 26 close | $139.63 | Base |
| IPO price · June | $135.00 | +3.4% |
| 52-week low · Aug. 3 | $104.83 | +33.2% |
Investor bridge
Louisiana expands Starship launch capacity for three revenue engines: external launch services, Starlink deployment and orbital AI infrastructure. The $100 billion headline equals all June liquidity and 3.5 times first-half capex.
Starship cadenceStarlink capacityAI satellitesExecution risks
No annual spending schedule, financing plan or return target was disclosed. Starship reusability, permits, wetland mitigation and launch demand must advance before the campus can earn a return.
engineeringregulationcash burnenvironmentProject checkpoints
| Checkpoint | Timing | What investors need |
|---|---|---|
| Phased budget | Not disclosed | Annual cash use, debt and partner funding |
| Permits and wetlands plan | Pre-construction | Schedule certainty and mitigation cost |
| Construction start | Expected 2027 | Evidence the plan is funded and active |
| Starship scale-up | Ongoing | Reliability, reusability and lower launch cost |
| First Louisiana launch | Targeted 2029 | Capacity begins supporting revenue channels |
Sources: Louisiana Economic Development’s Aug. 25 announcement; SpaceX Q2 2026 results; Reuters; WSJ delayed quote; Yahoo Finance Most Active; MarketBeat analyst record. Calculations use the Aug. 26 regular close and approximately $1.84 trillion quoted market value.
Oracle Shares Rise 2.8%, Market Value Grows by $12 Billion as Citi Highlights Key Catalysts Over Next 90 Days
New York, August 26, 2026, 19:49 – Oracle shares climbed 2.8%, increasing the company’s market capitalisation by $12 billion after Citi pointed to catalysts expected within the next 90 days.
Oracle: a $12 billion relief rally
Market snapshot: August 26, 2026, 19:49 EDT (August 27, 01:49 CEST). Regular-session figures unless noted.
Close
$148.87
+2.84%
Latest regular session
Value added
≈$12.0bn
Estimated from current shares
Market value
$433.5bn
August 26 close
Volume
18.4m
≈57% of recent average
The drawdown still dominates
Citi's 90-day setup
$330 target
+121.7% versus Wednesday's close
Forced selling may be fading.Credit spreads need to stabilize.At-the-market issuance remains a dilution test.Cloud delivery must turn backlog into billed revenue.
Fiscal 2026 growth engine
| Metric | Value | Growth |
|---|---|---|
| Total revenue | $67.4bn | +17% |
| Total cloud | $34.0bn | +39% |
| Cloud infrastructure | $18.1bn | +77% |
| Cloud applications | $15.9bn | +11% |
| RPO | $638bn | +363% |
RPO equals about 9.5 times annual revenue, but converts over several years.
Cash-flow bridge
| Operating cash flow | $32.0bn |
| Capital expenditure | −$55.7bn |
| Free cash flow | −$23.7bn |
| FY26 debt raised | $43bn |
| FY26 equity raised | $5bn |
| Planned FY27 financing | ≈$40bn |
Planned FY27 financing includes a previously announced $20bn at-the-market equity program.
Large-cap software and cloud tape
| Company | Close | Daily move | Market value | P/E |
|---|---|---|---|---|
| Oracle | $148.87 | +2.84% | $433.5bn | 26.7× |
| Microsoft | $496.37 | +0.91% | $3.70tn | 29.5× |
| Alphabet | $342.00 | −1.40% | $4.18tn | 17.2× |
| SAP ADR | $211.68 | −2.45% | $247.1bn | — |
August 26 U.S. close; latest trade timestamps ranged from 19:15 to 19:38 EDT.
Analyst range
$263.97
Average target across 39 analysts tracked by MarketBeat.
| Low | $145 |
| Average | $263.97 |
| High | $400 |
| Average implied upside | 77.3% |
What moved attention
August 26
Citi opened a positive 90-day catalyst watch. Oracle also held a financial analyst meeting at 10:45 CT.
Next 90 days
Investors will test cloud-capacity delivery, financing costs and signs that the historic selloff is losing force.
Investor scorecard
Backlog conversion: growth in cloud revenue versus the $638bn RPO balance.Capacity: new data-center and GPU deployment milestones.Cash: capital spending against operating cash generation.Funding: debt spreads, equity issuance and credit-rating pressure.
Risk register
| Risk | Investor transmission | Watch point |
|---|---|---|
| Build delays | Defers contracted revenue | Capacity delivery |
| Negative cash flow | Raises external-funding needs | Capex and OCF |
| Equity issuance | Dilutes existing holders | $20bn ATM program |
| Credit pressure | Increases financing costs | Spreads and ratings |
| Customer concentration | Raises contract and renewal sensitivity | RPO mix |
Sources: Oracle investor relations, Citi commentary reported August 26, Yahoo Finance, MarketBeat and consolidated U.S. market data. Market-value changes and peak-value gaps are estimates using the current implied share count; rounding may create small differences.
IREN Shares Rise 3.2% After Hours, Reducing Pre-Earnings Loss of $940 Million by Half
IREN Limited shares regained half of their decline from the regular session in after-hours trading on Wednesday. The stock climbed 3.21% to $40.85 at 19:34 EDT, having earlier finished the day 6.23% lower at $39.58.
IREN: the earnings-day setup
Market snapshot: August 26, 2026, 19:34 EDT (August 27, 01:34 CEST). Prices after the U.S. regular close.
Regular close
$39.58
−6.23%
4:00:01 p.m. EDT
After hours
$40.85
+3.21%
7:34:29 p.m. EDT
Implied late value
$14.60bn
About 357.4m implied shares
Volume
37.45m
82.2% of 45.55m three-month average
One session, three valuation points
The regular decline erased an estimated $940m. Late trading recovered about $454m, leaving roughly $486m below Tuesday's value.
What the late valuation assumes
<3.7×
Implied after-hours market value divided by management's above-$4bn year-end AI Cloud ARR target.
Contract coverage
About 85% of the target ARR is under contract. Weighted average term: roughly four years.
GPU-capex prepayments
Customer prepayments cover about 45% of associated GPU capital spending.
Thursday's estimate range
| Provider | Revenue | EPS |
|---|---|---|
| MarketBeat | $132.00m | −$0.55 |
| Zacks preview | $138.89m | −$0.80 |
These are separate provider forecasts, not a blended consensus. Results: August 27. Call: 5:00 p.m. EDT.
Last reported quarter
| Metric | Q3 FY26 | Q2 FY26 | Seq. |
|---|---|---|---|
| Revenue | $144.8m | $184.7m | −21.6% |
| Adjusted EBITDA | $59.5m | $75.3m | −21.0% |
| Net income/(loss) | −$247.8m | −$155.4m | Wider loss |
Quarter ended March 31, 2026. Lower Bitcoin prices and mining-hardware retirements weighed on results.
AI Cloud execution map
New contracts
$2.8bn
Multiyear AI Cloud agreements disclosed July 20
2026 delivery
480 MW
Up from roughly 3 MW
2027 target
1.2 GW
Planned energized capacity
June cash
$7.6bn
Includes $1.7bn restricted cash
U.S.-listed AI infrastructure peers
| Company | Close | Move | Value | Volume |
|---|---|---|---|---|
| IREN | $39.58 | −6.23% | $14.15bn | 37.45m |
| CoreWeave | $88.01 | −0.03% | $48.54bn | 12.13m |
| Nebius | $213.93 | −3.62% | $58.16bn | 9.17m |
August 26 U.S. regular close. Source: Yahoo Finance.
Analyst expectations
$83
Average target across 21 analysts tracked by MarketBeat.
| Low | $46 |
| Average | $83 |
| High | $105 |
Pre-results snapshot. Targets can change rapidly after earnings.
The four numbers that matter next
AI Cloud billed revenue: evidence that contracted ARR is converting on schedule.Deployment milestones: progress toward 480 MW during 2026.Funding bridge: remaining GPU capex after customer prepayments and restricted cash.Mining drag: the effect of Bitcoin prices and hardware retirements on cash generation.
Risk register
| Risk | Transmission to investors | Watch point |
|---|---|---|
| Delivery delay | Pushes contracted ARR recognition outward | Energization and GPU-install dates |
| Capital intensity | Raises financing or dilution risk | Capex, prepayments and unrestricted cash |
| Customer concentration | Increases renewal and counterparty sensitivity | New contract mix |
| Mining volatility | Obscures the AI Cloud transition | Bitcoin economics and retired capacity |
Sources: IREN filings and releases, Yahoo Finance, MarketBeat and Zacks. Market-value changes are estimates derived from Yahoo's August 26 closing price and market capitalization. Figures may differ because of rounding and after-hours liquidity.
Marvell Shares Jump 3.6% After Hours; Options Market Signals $22 Billion Earnings Move
SANTA CLARA, California, August 26, 2026, 18:04 – Marvell Technology stock gained 3.6% in after-hours trading, with options traders positioning for an anticipated $22 billion swing tied to the company’s upcoming earnings release.
NASDAQ:MRVL · Company · Stock move
Marvell: a $22 billion earnings hinge
Market snapshot: August 26, 2026, 18:03:50 EDT
After hours +3.62%
After-hours price
$253.97
+$8.86 from the close
Value added after close
≈$8.0B
Implied market cap ≈$228.2B
Options move
±10%
≈$22.0B from closing value
Q2 revenue consensus
$2.71B
About +35% year over year
Price path
Regular close: August 26 at 16:00:01 EDT. After-hours quote: 18:03:50 EDT. Total gain from the prior close: 5.65%.
What options are pricing
From the after-hours price, the options upper bound offered 6.2% upside. The lower bound represented 13.1% downside. The skew shows how Wednesday’s late rally consumed much of the bullish move.
Recent options signal published August 24, 2026; range recalculated from the August 26 closing price.
Fiscal Q2 setup
| Metric | Expectation / guide | Change |
|---|---|---|
| Revenue consensus | $2.71B | ≈+35% YoY |
| Adjusted EPS consensus | $0.93 | +38.8% YoY |
| Company revenue guide | $2.70B ±5% | +11.7% QoQ midpoint |
| Adjusted EPS guide | $0.93 ±$0.05 | $0.88–$0.98 |
| Non-GAAP gross margin | 58.25%–59.25% | 58.9% in Q1 |
| Diluted share count | 915M expected | Company guide |
Prior-quarter base
Q1 revenue growth
+28%
Q2 expected growth
+35%
Q1 non-GAAP GM
58.9%
Fiscal Q1 revenue was a record $2.418 billion. Non-GAAP net income reached $718 million, while operating cash flow hit a record $638.8 million.
The key test is conversion: exceptional AI bookings must become revenue without pushing gross margin below the guided range.
Valuation and analyst bar
| Measure | Value | Read-through |
|---|---|---|
| Trailing P/E | 84.2× | Premium leaves little room for a weak guide |
| Closing market cap / Q2 revenue | 81.3× | One quarter, not an annual multiple |
| Annualized Q2 price/sales | ≈20.3× | Assumes the quarter repeats |
| Yahoo one-year target | $266.36 | +4.9% from after-hours price |
| Susquehanna target | $265 | Positive; +4.3% from after hours |
| Rosenblatt target | $300 | Buy; +18.1% from after hours |
Price, P/E and consensus-target snapshot: August 26, 2026, 18:03:50 EDT. Fresh brokerage targets were reported August 25.
Google agreement: revenue versus dilution
Potential sales
Up to $120B
Warrant shares
58.97M
Q2 share dilution
6.4%
Google can buy the warrant shares at $206.58. Most vest only when product-purchase thresholds are met through fiscal 2033. Dilution is therefore tied to sales conversion.
Peer valuation at the August 26 close
| Company | Session move | Trailing P/E |
|---|---|---|
| Marvell | +1.97% | 84.2× |
| Nvidia | −1.52% | 31.9× |
| Broadcom | −0.33% | 97.6× |
| AMD | +0.36% | 123.6× |
Marvell sits between Nvidia and higher-multiple custom-compute peers. Its earnings must validate optical-networking growth and the custom-silicon pipeline.
Peer close data retrieved August 26, 2026, 17:52 EDT.
Thursday checklist
- Fiscal-year revenue guidance and any raise.
- Optical-interconnect sequential growth.
- Custom XPU and Google-linked revenue timing.
- Gross margin versus the 58.25%–59.25% range.
- Operating cash conversion after the Q1 record.
- Celestial AI and XConn acquisition contribution.
Risk map
Expectations: An in-line quarter may not support the multiple.
Margin: Memory and optical-component costs can compress profitability.
Execution: Custom silicon ramps require long design and qualification cycles.
Dilution: Google warrants equal 6.4% of guided diluted shares.
Tape: Regular volume was only 39% of the three-month average.
Next confirmed catalyst
Fiscal Q2 2027 results and conference call — August 27, 2026, 16:45 EDT. The market will compare any guidance raise with a $228 billion implied after-hours valuation and the 10% options move.
Sources: Yahoo Finance · Marvell Q1 results · Marvell event notice · Investopedia · Reuters
Nutanix Shares Rise 7.2% With Market Value Up $1.27 Billion After FY2027 Guidance Maintained
Nutanix Inc. shares rose 7.2% in after-hours trading on Wednesday. The hybrid-cloud firm surpassed analyst forecasts for both revenue and profit in the quarter.
NASDAQ: NTNX · Earnings reaction
Nutanix investor dashboard
Market data: Aug. 26, 2026, 17:22 EDT
Financials: quarter ended July 31, 2026
Financials: quarter ended July 31, 2026
After-hours price
$70.10
+$4.71 · +7.20%
Equity value added
$1.27B
Estimated from 270.32M shares
Trading activity
4.66M
1.88× 2.48M average volume
52-week position
74%
$34.01 low · $82.42 high
Quarterly surprise
| Metric | Actual | Consensus | Beat |
|---|---|---|---|
| Revenue | $757.1M | $738.3M | +$18.8M |
| Adjusted EPS | $0.60 | $0.49 | +$0.11 |
Growth and margin
Q4 FY2025Q4 FY2026
Operating scoreboard
| Metric | Q4 FY26 | Q4 FY25 | Change |
|---|---|---|---|
| Revenue | $757.1M | $653.3M | +16% |
| ARR | $2.55B | $2.20B | +16% |
| Adj. gross margin | 87.7% | 88.3% | −60 bps |
| Adj. operating margin | 26.2% | 18.3% | +790 bps |
| Free cash flow | $277.6M | $207.8M | +34% |
Fiscal 2027 guide
Revenue$3.18B–$3.23B
Midpoint growth12.5%
Adj. operating margin24%–25%
Free cash flow$850M–$950M
Q1 revenue$755M–$765M
Q1 adj. operating margin26%–28%
Implied market cap
$18.95B
At $70.10 after hours
FY27 sales multiple
5.9×
Using $3.205B midpoint
FY27 FCF multiple
21.1×
Using $900M midpoint
Analyst setup
Moderate Buy
18 ratings · $64.21 mean target before results
What moved the stock
Revenue exceeded consensus by 2.5%. Adjusted operating margin expanded 790 basis points. ARR kept pace with quarterly revenue at 16% growth. Fiscal-2027 guidance preserved double-digit sales growth while keeping adjusted operating margin near one quarter of revenue.
Risk monitor
Adjusted gross margin fell 60 basis points. Server supply constraints can delay deployments and cash collection. The after-hours price already exceeds the pre-report average analyst target. Extended-hours liquidity can exaggerate moves.
Sources: Nutanix fiscal Q4/FY2026 release; MarketBeat earnings estimates and analyst consensus; StockAnalysis after-hours quote and share data. Valuation figures are calculated estimates. Prices and volume are time-sensitive.
Veeva shares climb 8.2%, market value up $3.3 billion after AI-driven sales boost forecast
PLEASANTON, California, August 26, 2026, 17:41 EDT — Veeva Systems advanced 8.2%, adding $3.3 billion in market capitalization, after the company raised its sales outlook on the back of increasing demand for its artificial intelligence products.
NYSE: VEEV · Company stock move
AI and life-sciences cloud growth lift Veeva
Fiscal Q2 2027 earnings · closed market / after-hours reaction
Price snapshot: August 26, 2026, 17:40:48 EDT
Results and guidance: August 26, 2026
Results and guidance: August 26, 2026
After-hours price
$265.09
vs. $244.91 regular close
After-hours move
+8.24%
+$20.18 per share
Implied value added
≈$3.28B
162.44M shares × $20.18
Q2 revenue
$928.0M
+18% year over year
Quarterly operating scorecard
Q2 FY2026Q2 FY2027
Investor bridge
The after-hours value gain is about twice Veeva’s $1.6 billion annual adjusted operating-cash-flow guide.
FY2027 guidance reset
| Metric | Prior | New | Change |
|---|---|---|---|
| Revenue midpoint | $3.640B | $3.6845B | +$44.5M |
| Adjusted operating income | ≈$1.610B | ≈$1.640B | +$30M |
| Adjusted EPS | ≈$9.05 | ≈$9.21 | +$0.16 |
| Adjusted operating cash flow | — | ≈$1.600B | 43% margin |
Revenue mix and product signals
| Signal | Latest | Growth / status |
|---|---|---|
| R&D and Quality subscription | $419.4M | +19% |
| Commercial subscription | $347.4M | +13% |
| Vault CRM customers live | >180 | 5 top-20 live |
| Top-20 CRM commitments | 12 of 20 | 2 added in August |
| Falcon early adopters | 5 | Initial go-lives due in 2026 |
Street positioning
30 ratingsOverweight consensus16 Buy5 Overweight8 Hold1 Sell| Average target | $251.04 · 5.6% below |
| Median target | $266 · 0.3% upside |
| Target range | $165–$340 |
| Pre-report FY2027 EPS estimate | $9.06 |
| New company EPS guide | $9.21 |
Analyst snapshot dated August 26, 2026; comparisons use the 17:40:48 EDT after-hours price.
Risk monitor
- Growth cadence: Q3 revenue guidance implies roughly 15%, below Q2’s 18%.
- Valuation: the stock traded above the pre-report average target.
- CRM conversion: eight top-20 biopharma decisions remain outside the disclosed commitments.
- Operating exposure: competition, security failures or weaker drug funding could delay deployments.
- Cash timing: quarterly GAAP operating cash flow was nearly flat year over year.
Synopsys Shares Drop 2.8%, Wiping Out $2.2 Billion After Upgraded AI-Driven Outlook
SUNNYVALE, California, August 26, 2026, 17:27 — Synopsys slipped 2.8%, losing $2.2 billion in market value, after the company raised its forecast bolstered by AI-related business.
NASDAQ: SNPS · Company · Stock move · Earnings
Synopsys: a beat, a raise, and a $2.2B valuation warning
AI demand strengthened the numbers. The after-hours tape said the size of the raise still mattered.
August 26, 2026
17:31 EDT · After hours
17:31 EDT · After hours
After-hours price
$398.65
−2.77% · −$11.35
Regular close: $410.00
Equity value erased
$2.17B
After-hours
191.48M shares × $11.35
Q3 revenue
$2.477B
+42.4% YoY
1.6% above consensus
Adjusted EPS
$3.91
+6.5% vs estimate
$3.67 consensus · $3.39 YoY
The market's message
The quarter beat. The forecast raise was modest.The annual revenue midpoint increased by roughly $45M, or 0.47%. At about 95× trailing earnings, a small upgrade left little room for upside surprise.
Regular closePost-earnings move
Trading snapshot
Regular range$403.54–$419.60
Volume2.51M
Average volume1.81M
Volume vs average+38.7%
Market cap at close$78.51B
Trailing P/E95.0×
Where growth came from
Design Automation revenue$2.003B · +52.7%
80.9% of Q3 revenue · includes Ansys
Design IP revenue$473.8M · +10.8%
19.1% of Q3 revenue · returned to YoY growth
Margin signal
Non-GAAP operating margin41.6%
Design Automation margin45.2% · +70 bp
Design IP margin26.5% · +640 bp
GAAP operating margin14.4%
Large acquired-intangible amortization keeps the GAAP and adjusted views far apart.
Guidance bridge
| Metric | Prior | New | Midpoint change |
|---|---|---|---|
| FY2026 revenue | $9.63B–$9.71B | $9.69B–$9.74B | +$45M · +0.47% |
| FY2026 adjusted EPS | $14.72–$14.80 | $15.04–$15.10 | +$0.31 · +2.1% |
| Q4 revenue | — | $2.53B–$2.58B | New range |
| Q4 adjusted EPS | — | $4.10–$4.16 | New range |
| FY2026 free cash flow | — | ~$2.60B | 26.8% of revenue midpoint |
Catalyst scorecard
Revenue beatEPS beatGuide raisedIP growth restoredPositiveAI-led EDA demand
PositiveAnsys quarter
WatchOrganic mix
PressurePremium valuation
Analyst setup before revisions
Buy / Hold / Sell11 / 3 / 0
Average target$571.92
Upside from close39.5%
Target range$450–$650
Pre-earnings snapshot. New notes can change the distribution.
Peer valuation
Synopsys P/E95.0×
Cadence P/E66.6×
SNPS premium42.7%
SNPS AH move−2.77%
CDNS AH move+0.55%
What investors should watch next
1 · Design IP
Sequential growth in Q4Confirms that the recovery extends beyond one quarter.
2 · Ansys integration
$2.98B expected FY revenueSynergies must offset amortization, restructuring and leverage.
3 · Multiple support
95× trailing earningsHigh expectations make the stock sensitive to modest raises.
Sources: Synopsys fiscal Q3 2026 results; Reuters; Google Finance. Market figures timestamped August 26, 2026, 17:31 EDT. Price data may be delayed. Calculations use disclosed figures and may differ slightly because of rounding.
Nvidia Shares Drop 1.8% Following $96.2 Billion Quarterly Revenue, With AI Commitments Now at $366 Billion
SANTA CLARA, California, August 26, 2026, 16:30 EDT — Nvidia stock declined by 1.8% after reporting quarterly revenue of $96.2 billion, as the company’s total AI-related commitments reached $366 billion.
NVIDIA · NASDAQ:NVDA · Q2 FY2027
Revenue beat, balance-sheet test
Market data: Aug. 26, 2026, 16:30 EDT
Financials: quarter ended July 26, 2026
Financials: quarter ended July 26, 2026
After hours
$205.92 · -1.78%
Close $209.66 · about $90B value erased
Q2 revenue
$96.22B
+106% YoY · +4.2% vs FactSet consensus
Q3 outlook
$108.0B
+3.6% vs $104.2B consensus · ±2% range
Commitments + guarantees
$474.5B
8.4× cash and marketable debt securities
Revenue acceleration
Q2 Data Center revenue was $89.0B, or 92.5% of total sales.
Investor bridge
| Measure | Value | Signal |
|---|---|---|
| Adjusted EPS | $2.22 | +6.2% vs est. |
| Q2 gross margin | 75.0% | Flat QoQ |
| Q3 gross margin | 74.0% | -1.0 pt |
| Free cash flow | $21.34B | -56% QoQ |
| DSO | 60 days | +15 days |
Commitment stack
Supply and capacity · $279B
Other contractual commitments · $87B
Contingent guarantees · $108.5B
Supply commitments rose $160B, or 134%, in one quarter. The guarantee total includes $105B for the Ohio site and $3.5B for AI-cloud leases.
Operating signals
| Metric | Q2 FY27 | Sequential | Why it matters |
|---|---|---|---|
| Data Center | $89.0B | +18% | Core demand remains strong |
| ACIE | $40.3B | +25% | Faster than hyperscale |
| Receivables | $63.1B | DSO 45→60 | Cash conversion slowed |
| Inventory | $31.6B | +22% | Rubin launch build |
| Operating cash flow | $24.1B | -52% | Working capital and taxes |
What changes the thesis
Bull: $108B revenue converts to cashBull: ACIE sustains 25% QoQ growthBear: margin falls below 73.5%Bear: DSO extends againBear: customer guarantees activate
Commitments are future obligations, not immediate debt. Guarantees are contingent. The valuation test is whether Nvidia's revenue and free cash flow scale faster than supply, lease and customer-support exposure.
Generate Biomedicines Stock Slides 20% as 103 Million Shares Clear Lock-Up
Generate Biomedicines Inc. shares fell 20.3% to $16.25 at 15:06 EDT. The decline erased about $530 million of quoted equity value.
NASDAQ: GENB · Investor dashboard
Lock-up supply resets the valuation debate
A 103.14 million-share resale block became eligible as Generate Biomedicines returned near its $16 IPO price. The September 8 GB-0895 data now become the next fundamental test.
Market snapshot
Aug. 26, 2026 · 15:06 EDT
Aug. 26, 2026 · 15:06 EDT
STOCK MOVELOCK-UP
Share price
$16.25
Aug. 26, 15:06 EDT
Session move
−20.3%
−$4.13 per share
Volume
3.06M
3.4× 3-month average
Market value
$2.09B
At 15:06 EDT
Information gain: the day’s $4.13 decline erased roughly $530 million of quoted equity value. The unlocked block itself was worth about $1.68 billion at $16.25.
Potentially sale-eligible share pool
SEC share count: 128.27M at June 30, 2026. Eligibility does not prove actual selling.
Price path: rally, reversal, reset
Aug. 21 close
$16.12
Aug. 24 close
$17.72
Aug. 25 close
$20.38
Aug. 26, 15:06
$16.25
GENB rose 26.4% from Aug. 21 through Aug. 25, then gave back nearly the entire advance. It remained 1.6% above the $16 IPO price at 15:06 EDT on Aug. 26.
Balance-sheet and operating signals
| Metric | Latest | Investor read |
|---|---|---|
| Cash + securities | $457.4M | 21.9% of market cap |
| H1 operating cash use | $138.3M | Runway into H1 2028 |
| Q2 collaboration revenue | $6.3M | −37.7% year over year |
| Q2 net loss | $67.3M | Widened from $56.7M |
| Q2 GB-0895 external R&D | $20.5M | +54.3% year over year |
Catalyst clock
Feb. 27IPO priced at $16; 25M shares sold for $400M gross.
Aug. 25 closeRestrictions lift on 103.14M shares, subject to securities laws.
Sept. 8GB-0895 Phase 1b COPD safety, PK and PD poster at ERS 2026.
H1 2028Management’s current cash-runway horizon and planned Phase 3 enrollment window.
What changes next: ownership supply drove this session. September data can shift the focus back to GB-0895’s pharmacology and the twice-yearly dosing case.
Analyst expectations
Average target
$25.60
Six analysts
Target range
$22–$30
S&P Global poll
As of Aug. 26, 2026. Morgan Stanley reiterated Buy with a $22 target on Aug. 17; Piper Sandler reiterated Buy with a $24 target on Aug. 7.
Investor frame
Bull case: little actual lock-up selling would make the 20% drop look like a temporary supply discount. Positive COPD data could strengthen the six-month dosing proposition ahead of larger severe-asthma readouts.
Risk case: sustained insider or venture-holder sales could cap rebounds. Weak September pharmacology, faster cash use, or Phase 3 delays would raise financing and dilution risk before commercialization.
Mitsubishi Motors Shares Up 2.5% Before 2027 Pajero Launch
Mitsubishi Motors is set to debut the 2027 Pajero on September 2. The flagship SUV makes a comeback to international markets after a five-year absence. Shares of Mitsubishi Motors Corporation finished Wednesday at ¥374.70, rising 2.52%.
Product catalyst · TYO:7211
2027 Mitsubishi Pajero
Flagship SUV return meets a low-margin growth plan.
Market data: August 26, 2026, 15:30 JST · Dashboard: August 27, 2026, 03:42 JST
Close
¥374.70
▲ 2.52%
Tokyo close, Aug. 26
Session volume
8.57M
shares traded
Market value
¥501.6B
approximate; 1.34B shares
Analyst target
¥372.83
0.5% below the close
Wednesday's price action
Open¥364.20
Low¥362.00
High / close¥374.70
Equity-value gain≈¥12.3B
Equity-value change uses the ¥9.20 share gain and 1.34 billion shares outstanding.
Fiscal 2026 operating frame
Retail volume857,000 · +8%
Net sales¥3.26T · +13%
Operating profit¥90B · +19%
Operating margin2.8% vs. 2.6%
Sensitivity: 10 basis points of margin on ¥3.26 trillion equals ¥3.26 billion, or 3.6% of guided operating profit.
Pajero commercial signal
| Signal | Verified measure |
|---|---|
| Global return | After 5 years |
| Lifetime sales | >3.25M units |
| Historical markets | >170 |
| Dakar record | 12 wins |
| Platform | Triton ladder frame |
| Drive control | S-AWC |
Lifetime Pajero sales equal 3.8 times Mitsubishi's current full-year volume target.
What the market still needs
AUG 24
Teaser updateReveal date and triple multi meter confirmed.
SEP 2
World premierePricing, powertrain and initial markets are key.
H2 FY26
Launch phaseManagement links Pajero to sales growth.
FY26
Plan test857,000 retail units and 2.8% margin.
Risk watch: procurement and shipping are a ¥28.7 billion headwind. Delays, discounting or costly launch inventory would press a narrow margin target.
Analyst expectations
2 Buy7 Hold3 Sell12-analyst poll, accessed August 26
Target range¥330–¥500
Average target¥372.83
52-week trading range¥300.70–¥458.00
Sources: Mitsubishi Motors official Pajero site and releases; Mitsubishi Motors Q1 presentation summary; StockAnalysis and Investing.com market and consensus data. Currency is Japanese yen. Estimates are explicitly marked.
Rasonque FDA Approval Lifts Revolution Medicines Stock 0.8% at $45.7 Billion Valuation
Rasonque won U.S. approval Wednesday, giving Revolution Medicines, Inc. its first commercial product. The stock rose 0.77% to $213.01 at 11:55 a.m. EDT.
Rasonque approval dashboard
Revolution Medicines moves from trial risk to launch risk
NASDAQ:RVMD · PRODUCT/COMMERCIAL CATALYST
Market data: August 26, 2026
11:55 EDT / 17:55 Europe/Warsaw
11:55 EDT / 17:55 Europe/Warsaw
RVMD price
$213.01
+$1.63 · +0.77%
Market value
$45.65B
≈ $351M added today
Session range
8.3%
$198.91 low · $216.50 high
Volume by 11:55
1.10M
64% of 1.71M daily average
Session price map
Range positions are scaled from the verified session low and high. This is not a minute-by-minute price chart.
What changed
Rasonque is now a first-in-class, once-daily oral RAS inhibitor for certain adults with metastatic pancreatic cancer.
First product revenueNow possible
PricingNot disclosed
AvailabilityNot disclosed
Expanded-access patients2,000+
Phase 3 survival comparison
Rasonque median overall survival13.2 months
Standard chemotherapy6.7 months
Absolute improvement+6.5 months
Relative improvement+97%
Trial population500 adults
Valuation versus operating base
| Metric | Amount | Ratio to market cap |
|---|---|---|
| Quoted market value | $45.65B | 100% |
| Cash and securities, June 30 | $3.94B | 8.6% |
| 2026 operating-expense midpoint | $2.15B | 4.7% |
| Q2 operating expenses | $505.1M | 1.1% |
| Q2 net loss | $644.4M | 1.4% |
Cash equals 1.83× the midpoint of the current annual expense guide. It is not a formal runway estimate.
Analyst expectations
Buy ratings18
Hold ratings1
Average target$222.89
Implied upside4.6%
Target range$179–$291
Based on Google Finance’s 19-analyst, three-month set at the market-data timestamp.
What the valuation requires
Launch pricing and reimbursementNear term
Initial prescriptions and net salesNext reports
First-line pancreatic expansionPhase 3
RAS-mutant lung cancer readoutExpected 2027
Broad peak-sales estimate>$20B
The >$20B estimate assumes success beyond today’s approved patient group; current market value is about 2.3× that figure.
Catalyst timeline
Phase 3 survival data established the approval case.
Company reported U.S. launch readiness and $3.94B liquidity.
FDA approved Rasonque for the initial metastatic setting.
Pricing, availability, reimbursement and prescription uptake.
Risk monitor
Commercial
Pricing remains unknown. Slow coverage decisions can defer revenue even after approval.
Execution
Manufacturing limits or weak real-world uptake would pressure launch estimates.
Valuation
The average analyst target offers only 4.6% upside. Failed expansion trials would narrow the revenue base.
Investor bridge
Approval creates the first direct sales channel for Revolution Medicines. The financial test is whether Rasonque’s launch and later-label expansion can grow into a $45.65 billion valuation while annual operating expenses run near $2.15 billion.
Apple Shares Gain 1.1% as Mac mini M6 Launches with 12.5% Price Increase to $899
Apple's Mac mini featuring the new M6 comes at a steeper price for its compact desktop line. Apple Inc. stock gained 1.1% to $313.37 on Wednesday.
Mac mini with M6 · Apple NASDAQ:AAPL
A 12.5% price test for a record Mac business
Company · Product/commercial catalyst
Market data: August 26, 2026, 11:11:19 EDT
Financials: fiscal Q3 ended June 27, 2026
Financials: fiscal Q3 ended June 27, 2026
AAPL price
$313.37
+$3.47 · +1.12%
Nasdaq real-time, market open
Mac mini M6
$899
+$100 · +12.5%
U.S. starting price versus predecessor
Mac revenue
$10.4B
+28.7% year over year
Record June quarter
Market value
$4.573T
About $50.6B added at 11:11 EDT
The launch connects pricing to local-AI demand
Consumer entryProfessional AI mix
Mac's financial weight
Mac share of Q3 revenue9.5%
Mac year-over-year growth28.7%
$100 price rise / old $799 base12.5%
One point of quarterly Mac growth≈$104M
Latest company signals
| Fiscal Q3 2026 | Value | YoY |
|---|---|---|
| Revenue | $109.4B | +16% |
| Net income | $29.8B | +27% |
| Diluted EPS | $2.02 | +29% |
| Gross margin | 50.1% | +3.6 pts |
| Mac revenue | $10.4B | +28.7% |
Gross margin included an approximately two-point tariff-refund benefit.
Investor transmission map
Higher priceA $100 increase supports revenue per unit.
AI performanceM6 targets local models and always-on agents.
Memory costsComponent inflation can absorb pricing gains.
Unit demandA 12.5% entry-price rise can slow volumes.
Stock and valuation
Session range$308.80–$313.45
Volume at 11:06 EDT7.20M
Average volume55.95M
Trailing P/E35.94×
52-week range$225.95–$344.57
Analyst expectations and next checks
S&P Global consensusBuy
Average target$326.34
Target upside at timestamp4.1%
Estimated earningsOctober 29, 2026
Risks
Apple gives no Mac mini unit or revenue forecast. Higher prices may weaken demand. Memory constraints can delay shipments or pressure margins. Product claims are based on Apple's controlled tests.
The Witcher 3 Remastered Is Free; CD Projekt Shares Slip 0.8% on Heavy Volume
The Witcher 3: Wild Hunt — Remastered gives CD Projekt S.A. a low-price acquisition tool for its 2027 paid expansion. The upgrade is free for existing owners, but opens two new storefronts and refreshes a game with 65 million lifetime sales.
WSE: CDR · Product catalyst
The Witcher 3: Wild Hunt — Remastered
A free September upgrade expands the funnel for a paid 2027 expansion.
Market snapshot
Aug. 26, 2026 · 15:23:28 CEST
Aug. 26, 2026 · 15:23:28 CEST
Share price
240.90 zł
−0.82% · −2.00 zł
Range 240.00–246.70 zł
Trading activity
395.85K
1.39× average daily volume
Average: 285.26K shares
Installed base
65M+
Lifetime Witcher 3 copies sold
Analyst case
70–75M
Potential base before 2027 expansion
From free upgrade to paid-content revenue
Sept. 29
Free remaster
Free remaster
→
New reach
Switch 2 + Battle.net
Switch 2 + Battle.net
→
2027
Paid Songs of the Past
Paid Songs of the Past
Launch facts
Gamescom reveal and trailer.
Original expansions become free for existing owners.
Remaster launches; new native Switch 2 and Battle.net editions.
Paid Songs of the Past expansion.
Q1 2026 economics
| Metric | Value | YoY |
|---|---|---|
| Group revenue | 191.1M zł | +6% |
| Witcher IP revenue | 44.7M zł | +36% |
| Witcher share of sales | 23.4% | +5.2 pts |
| Net profit | 106.2M zł | −5% |
| Cash/deposits/bonds | 1.41B zł | +6% q/q |
Stock and valuation
| Signal | Reading |
|---|---|
| Market cap | 24.01B zł |
| Quoted value lost today | ≈199.8M zł |
| Trailing P/E | 39.41× |
| 52-week range | 211.30–297.00 zł |
| Shares outstanding | 99.91M |
| Erste view | Meaningful positive Q4 impact |
Investor interpretation
| Driver | Upside | Constraint |
|---|---|---|
| Free remaster | Reactivates a 65M-player catalogue | No upgrade revenue from existing owners |
| New platforms | Incremental unit sales and distribution | Platform royalties and launch costs |
| Paid 2027 expansion | Monetizes a larger installed base | Pricing and release date undisclosed |
| 2028 Witcher 4 target | Extends franchise roadmap | Long flagship-release gap |
Risk check
The 70–75 million-copy figure is an analyst estimate. A free update can lift engagement without converting into enough new purchases or expansion sales.
Attention signal
Google Trend: “the witcher 3 wild hunt remastered” · Canada, active at selection; trading volume already above average.
Sources: CD Projekt announcement and Q1 2026 presentation; Reuters, Aug. 26, 2026; Google Finance at 15:23:28 CEST. Time-sensitive figures are timestamped above.
Boston Scientific Shares Drop 4.1% After Cyberattack Threatens Up to $369 Million in Q3 Revenue
NEW YORK, August 26, 2026, 09:40 – Shares of Boston Scientific fell 4.1% after the company disclosed that a cyberattack may endanger as much as $369 million in third-quarter sales.
NYSE: BSX · Cyberattack monitor
Boston Scientific
Order-processing and shipment disruption meets a reduced 2026 growth outlook.
Market snapshot
Aug. 26, 2026 · 09:40:21 EDT
Aug. 26, 2026 · 09:40:21 EDT
Share price
$47.81
−4.11% · −$2.05
Open $47.00 · range $46.90–$48.53
Quoted value lost
$2.97B
Estimated from 1.45B shares outstanding
Q3 revenue guide
$5.22–$5.32B
3%–5% growth vs. Q3 2025
Revenue risk scenario
$316–$369M
Evercore: 600–700 bp if recovery mirrors Stryker
Market repricing versus modeled sales exposure
The stock-market loss equals roughly 8.0×–9.4× the analyst's modeled revenue exposure.
Market valueLow scenarioHigh scenario
What moved the stock
Company detects a cybersecurity incident.
Discloses global disruption, including systems that process and ship orders.
Shares open at $47.00, 5.74% below prior close.
BSX trades at $47.81, down 4.11%.
Operating base
| Metric | Q2 2026 | YoY |
|---|---|---|
| Total sales | $5.442B | +7.5% |
| Cardiovascular | $3.624B | +8.3% |
| MedSurg | $1.818B | +5.9% |
| Adjusted EPS | $0.86 | +14.7% |
| GAAP net income | $907M | +13.8% |
Guidance and valuation
| Signal | Current reading |
|---|---|
| FY26 sales growth | 5.5%–6.5% reported |
| FY26 adjusted EPS | $3.28–$3.32 |
| Q3 adjusted EPS | $0.80–$0.82 |
| P/E | 19.38× |
| Analyst consensus | Buy · 31 analysts |
| Average target | $62.69 · 31% upside |
Scenario frame
| Recovery path | Revenue effect | Investor implication |
|---|---|---|
| Faster than Stryker | Below $316M | More orders may shift within the quarter rather than disappear. |
| About three weeks | $316M–$369M | Evercore's 600–700 bp scenario; a guide cut becomes plausible. |
| Longer or broader | Above $369M | Margin pressure and customer disruption could outlast shipment delays. |
Risk check
Boston Scientific has not determined whether the incident is reasonably likely to be material. The full scope, recovery duration and any data loss remain unknown.
Watch next: recovery timetable, shipment resumption, order recapture, guidance update.
Sources: Boston Scientific Q2 2026 results; Reuters, Aug. 26, 2026; Google Finance quote at 09:40:21 EDT; StockAnalysis analyst consensus. The $316M–$369M range is a scenario calculation, not company guidance.
Callaway Golf shares slip 2% amid $430 million equipment division’s exposure to Quantum Driver ad campaign
CARLSBAD, California, August 26, 2026, 05:45 – Callaway Golf stock declined 2% on Wednesday following market reaction to ad pull testing related to its Quantum Driver, putting the company’s $430 million equipment segment under pressure.
Callaway Golf Company · NYSE:CALY
Quantum campaign fallout
A compact view of the stock reaction, the $699.99 co-branded driver, and the equipment segment carrying most of Callaway's quarterly revenue.
Market data: Aug. 26, 2026, 08:21:15 EDT
Financials: quarter ended Jun. 30, 2026
Financials: quarter ended Jun. 30, 2026
Aug. 25 close
$15.47
−2.03% · −$0.32
Official close, 16:00:03 EDT
Premarket
$15.56
+0.58% · +$0.09
Aug. 26, 08:21:15 EDT
Volume
1.27M
59% of 2.14M average
Aug. 25 session
Market value
$2.78B
Est. $57.1M erased
32¢ × 178.51M shares
Investor bridge: market loss versus equipment economics
Product and catalyst
Limited driver
$699.99
Good Good Quantum Triple Diamond Max, 460cc head, adjustable 10g weight.
Ad withdrawnCEO apologyTwo investigationsApproval changes
Golf Equipment — Q2 2026
| Metric | Result |
|---|---|
| Revenue | $430.3M · +4.5% |
| Operating income | $100.3M · +31.6% |
| Operating margin | 23.3% · +480 bp |
| Share of group sales | 70.3% |
Group signals
| Metric | Result |
|---|---|
| Q2 sales | $612.2M · +2.0% |
| GAAP gross margin | 50.1% · +620 bp |
| FY26 sales guide | $2.045B–$2.070B |
| FY26 adjusted EBITDA | $246M–$260M |
Analyst expectations
Consensus
Buy
| Average target | $20.50 |
| Implied upside from $15.47 | 32.5% |
| Coverage | 11 analysts |
| Rating mix | 5 Strong Buy · 5 Hold · 1 Sell |
S&P Global consensus, accessed Aug. 26, 2026.
Catalyst timeline
Aug. 21Good Good posts the co-branded driver video; it is removed within hours.
Aug. 22Good Good and Callaway issue preliminary responses.
Aug. 25Chip Brewer accepts Callaway's approval role and announces internal and external reviews.
Next evidenceProduct availability, partner actions and Callaway's next sales update.
What can change the thesis
Contained case: investigations close without retailer, media or partner withdrawals; the 0.58% premarket rebound persists. Adverse case: partner action raises campaign costs or weakens demand in a segment producing 70.3% of quarterly sales. Watch the product listing, PGA Tour decisions and management's next equipment-sales commentary.
Take-Two Faces $8.2 Billion Revenue Test with GTA 6 Netflix Launch
NEW YORK, August 26, 2026, 05:20 EDT — Take-Two Interactive’s projected $8.2 billion in bookings comes into focus as the gaming giant prepares for the Netflix premiere of Grand Theft Auto 6, a major release the company hopes will reinforce its revenue outlook.
Product catalyst · Investor dashboard
GTA VI’s Netflix preview meets Take-Two’s bookings test
A six-hour streaming exclusive concentrates attention before the November launch. The financial question is conversion, not trailer views.
Market data: Aug. 25, 2026, 16:00 EDT
Prepared: Aug. 26, 2026, 05:20 EDT
Prepared: Aug. 26, 2026, 05:20 EDT
TTWO close
$232.93
−0.24%
Aug. 25 regular session
After hours
$233.58
+0.28%
Latest verified quote: 16:54 EDT
Equity value
$43.55B
Approximate market capitalization
Netflix head start
6 hours
3 p.m. to 9 p.m. EDT, Aug. 27
The event
Grand Theft Auto VI: An Extended Look premieres to Netflix members at 3 p.m. EDT Thursday.
Public release9 p.m. EDT · YouTube + GTA VI site
Game launchNov. 19, 2026
Standard / Ultimate$79.99 / $99.99
Edition premium25.0%
Fiscal 2027 bookings bridge
Q1 bookings$1.39B
Full-year guidance$8.0B–$8.2B
Still required after Q1$6.61B–$6.81B
Q1 equals 17.2% of the $8.1B guidance midpoint. GTA VI launches during the fiscal year.
Price position inside 52-week range
The average analyst target sits above the current 52-week high. That requires execution beyond a successful marketing event.
Franchise scale
470M+
Grand Theft Auto units sold-in worldwide
GTA V alone230M+
Preorders“Unprecedented”
Published unitsNot disclosed
Illustrative launch spending
| Units | Standard | Ultimate |
|---|---|---|
| 10M | $0.80B | $1.00B |
| 25M | $2.00B | $2.50B |
| 50M | $4.00B | $5.00B |
Gross consumer spending before platform fees, tax, refunds and edition mix. Not company guidance.
Analyst expectations
Strong Buy| Buy / Hold / Sell | 27 / 0 / 1 |
| Average target | $286.89 |
| Implied upside | 23.2% |
| Low / High | $170 / $368 |
Why investors care
Take-Two needs a sales curve, not merely a cultural moment.
Preview qualityA weak showcase may slow preorder momentum.
ConversionSix hours of exclusivity may not produce measurable subscriptions.
ScheduleAnother delay would push bookings and cash flow outward.
VisibilityPreorder units remain undisclosed and cancellable.
Sources: Take-Two investor relations and preorder release; Netflix Tudum; Reuters; StockAnalysis; Investing.com. Scenario calculations are illustrative. Prices are in U.S. dollars.
Super Micro Shares Rise 9.35% After Cisco Announces October AI Factory Channel Launch
Super Micro Computer, Inc. gained 9.35% after Cisco launched an enterprise channel for its AI servers. Shares ended Tuesday at $38.46. Trading volume was 48.2 million shares.
Super Micro Computer · NASDAQ: SMCI
Cisco channel turns rack-scale AI demand into a margin test
Cisco begins offering Supermicro compute inside Secure AI Factory with NVIDIA in October 2026.
Market data: Aug. 25, 2026, 16:00 EDT
After-hours: 19:59 EDT
After-hours: 19:59 EDT
Close
$38.46
+$3.29 · +9.35%
Quoted value added
$2.13B
646.87M shares × $3.29
Trading activity
47.6M
Aug. 25 volume; 48.2M from consolidated snapshot
After-hours
$38.58
+0.30%
Seven-session price path
CloseObserved session
Quarterly operating pulse
| FY26 | Revenue | Gross margin | Net income |
|---|---|---|---|
| Q1 | $5.0B | 9.3% | $168M |
| Q2 | $12.7B | 6.3% | $401M |
| Q3 | $10.2B | 9.9% | $483M |
| Q4 | $11.1B | 17.5% | $1.18B |
Company-reported GAAP data; fiscal year ended June 30, 2026.
Guidance and balance-sheet signals
FY27 revenue guide$65B–$72B
Midpoint growth vs. FY26+75%
Q1 FY27 revenue guide$14.5B–$15.5B
FY26 cash$7.5B
Bank debt + convertibles$8.7B
Q4 operating cash flow$747M
AI infrastructure read-through · Aug. 25 close, 16:00 EDT
| Company | Close | Daily move | Signal |
|---|---|---|---|
| Super Micro (SMCI) | $38.46 | +9.35% | Cisco channel |
| Dell (DELL) | $451.50 | +4.23% | Server peer |
| HPE (HPE) | $53.44 | +1.93% | Server peer |
| Cisco (CSCO) | $111.11 | +0.80% | Platform owner |
Catalyst clock
AUG 11
Fiscal Q4 results17.5% gross margin; FY27 revenue guide reaches $72B.
AUG 25
Cisco partnershipRack-scale liquid- and air-cooled compute enters Secure AI Factory.
OCTOBER
Commercial availabilityFirst announced month for Cisco to offer Supermicro systems.
Investor takeaway
The Cisco channel validates Supermicro’s rack-scale position, but Tuesday’s $2.13B value gain arrived before any disclosed orders.
The clean confirmation would be sustained enterprise revenue plus gross margin near Q4’s 17.5%, rather than a return toward the 6%–10% range seen earlier in fiscal 2026.
The clean confirmation would be sustained enterprise revenue plus gross margin near Q4’s 17.5%, rather than a return toward the 6%–10% range seen earlier in fiscal 2026.
TechStock² Updates
